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Abstract
Background: Congenital combined pituitary hormone deficiency (CPHD) is a rare heterogeneous group of conditions.
CPHD-type 3 (CPHD3; MIM# 221750) is caused by recessive mutations in LHX3, a LIM-homeodomain transcription factor
gene. The isoforms of LHX3 are critical for pituitary gland formation and specification of the anterior pituitary hormone-
secreting cell types. They also play distinct roles in the development of neuroendocrine and auditory systems.
Case presentation: Here, we summarize the clinical, endocrinological, radiological and molecular features of three patients
from two unrelated families. Clinical evaluation revealed severe CPHD coupled with cervical vertebral malformations (rigid
neck, scoliosis), mild developmental delay and moderate sensorineural hearing loss (SNHL). The patients were diagnosed
with CPHD3 based on the array of hormone deficiencies and other associated syndromic symptoms, suggestive of
targeted LHX3 gene sequencing. A novel missense mutation c.437G > T (p. Cys146Phe) and a novel nonsense mutation c.
466C > T (p. Arg156Ter), both in homozygous forms, were found. The altered Cys146 resides in the LIM2 domain of the
encoded protein and is a phylogenetically conserved residue, which mediates LHX3 transcription factor binding with a zinc
cation. The p. Arg156Ter is predicted to result in a severely truncated protein, lacking the DNA binding homeodomain.
Conclusions: Considering genotype/phenotype correlation, we suggest that the presence of SNHL and limited neck
rotation should be considered in the differential diagnosis of CPHD3 to facilitate molecular diagnosis. This report describes
the first LHX3 mutations from Saudi patients and highlights the importance of combining molecular diagnosis with the
clinical findings. In addition, it also expands the knowledge of LHX3-related CPHD3 phenotype and the allelic spectrum
for this gene.
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Background
Combined pituitary hormone deficiency (CPHD) refers
to a rare heterogeneous group of conditions, which is
characterized by true deficiency of at least two anterior
pituitary hormones. CPHD has been linked with abnor-
malities in the genes encoding both signaling molecules
and transcription factors, which have been shown to play
a role in the development and maturation of the
pituitary gland. These genes include HESX1, LHX3,
LHX4, POU1F1, PROP1, SIX6, OTX2, PTX2, GLI2 and
SOX3 [1–3]. The pituitary phenotype caused by genetic
defects in these genes may be isolated (pure pituitary
phenotype) or may be associated with variable extrapi-
tuitary maifestations (syndromic CPHD) [4]. Clinical
presentation is variable, depending on the type and
severity of deficiencies and at the age of diagnosis. If
untreated, main symptoms usually include short stature,
cognitive alterations or delayed puberty. CPHD is related
to significant morbidity, especially hypoglycemia and its
consequences in newborns. Treatment should be started
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immediately and a strict specialized follow-up is neces-
sary [5]. Here, we describe the clinical, endocrinological,
radiological and molecular features of three new cases of
LHX3-related CPHD3.
Mutations in the LHX3 gene (MIM# 600577), located
on chromosome 9q34.3, underlie combined pituitary
hormone deficiency type 3 (CPHD3, MIM# 221750).
The encoded protein (Uniprot: Q9UBR4) is a LIM-
homeodomain (LIM-HD) transcription factor, which
features two amino-terminal LIM domains (cysteine-rich
zinc-binding domain) and a centrally-located DNA-
binding homeodomain [6]. In addition, the LHX3 pro-
tein also possesses a carboxyl terminus that includes the
major trans-activation domain. Alternative splicing gen-
erates two isoforms, LHX3a and LHX3b, which are 397
and 402 amino acids long, respectively. These isoforms
possess identical LIM domains, homeodomains and
carboxyl termini but possess different amino-termini
and differentially activate pituitary gene targets [7, 8].
Typically, genetically-confirmed CPHD3 patients with
homozygous LHX3 mutations present with hypopituitarism
including deficiencies in the growth hormone (GH), thyroid
stimulating hormone (TSH), prolactin (PRL), leutinizing
hormone (LH), follicular stimulating hormone (FSH) and
abnormal pituitary morphology. Adrenocorticotrophic
hormone (ACTH) deficiency, cervical abnormalities with or
without restricted neck rotation and sensorineural hearing
loss (SNHL) has also been reported in a subset of these
patients. The phenotypes in three patients (aged 2–11 year)
in this report include CPHD, rigid cervical spine, restricted
neck rotation, scoliosis, mild developmental delay and
congenital hearing impairment. Targeted sequencing of the
LHX3 gene revealed two novel recessive variants in these
patients. Finally, we surveyed the functional consequences
of these mutations.
Case presentation
We ascertained three patients with syndromic symptoms
associated with CPHD. An informed written consent
was used to recruit the patients and their family mem-
bers. All affected patients underwent detailed examin-
ation at the departments of clinical genetics and
pediatrics of King Faisal Specialist Hospital and Research
Centre, Riyadh, Saudi Arabia. Laboratory testing, radio-
logical investigation (X-ray) and audiologic assessments
were performed. Pituitary examination was made by
multisequential multiplanar magnetic resonance imaging
(MRI) by applying standard scanning protocols [9]. The
hormonal tests were measured by radioimmunoassay
techniques by Roche Diagnostics, USA. Hormonal evalu-
ation included basal levels for GH response to glucagon
stimulation, TSH, PRL, LH, FSH, cortisol, ACTH and
free thyroxine (FT4) levels. Growth biochemical markers
including insulin growth factor 1 (IGF1) and insulin
growth factor binding protein 3 (IGFBP3) were also
assessed. The diagnoses of hormonal deficiencies were
established using the normal range as cutoff limits: Basal
GH (>10 μg/L), TSH (0.27–4.2 mU/L), PRL (2.5–15 μg/L),
LH (0.1–3.3 U/L), FSH (0.1–7 U/L), ACTH (5–60 ng/L),
cortisol (190–750 nmol/L), FT4 (12–22 pmol/L), IGF1
(115–498 ng/L) and IGFBP3 (0.7–3.6 mg/L).
Cases
Patient 1, Family 1
This boy (II:2, Fig. 1a) was a product of an uneventful
pregnancy and normal vaginal delivery at 39 weeks of
gestation, whose healthy consanguineous parents had
previously lost a daughter in infancy probably because of
the same condition. At birth, he was noted to have a
micropenis with a stretched penile length of 1.8 cm and
undescended testes. Other dysmorphic features included
short webbed neck with limited rotation and triangular
face. During hypoglycemic attack at the 3rd month of the
life, ACTH and GH deficiencies were diagnosed. Later
TSH and gonadotropin deficiencies were also found (see
Table 1). Both TSH and FT4 were low suggesting central
hypothyroidism. MRI of pituitary gland showed a small
cystic lesion replacing the adenohypophysis of the pituit-
ary gland representing developmental cystic abnormality.
The pituitary stalk was present with normally placed
neurohypophysis. Skeletal survey showed closure of
sagittal suture causing dolichocephaly and hypoplasia of
the facial bones. Thyroxine (25 μg daily), hydrocortisone
(2.5 mg twice daily) and subcutaneous injections for GH
(0.035 mg/kg/day) were initiated to normalize glycemia
and to improve somatic growth at the 5th month of age.
His height was 107 cm at age of 7 years (on the 5th per-
centile, −2SD). Testosterone therapy was given at a dose
of 25 mg monthly for 3 months, which improved penile
length to 3.1 cm. He also had moderate SNHL at the
age of 2 years.
Patient 2, Family 2
The proband (II:2, Fig. 1b) of family 2 is the second child
of healthy first degree parents, born via normal vaginal
delivery at 39 weeks of gestation. He was initially evalu-
ated in a local hospital for mild hypoglycemic attacks
which were associated with jitteriness and irritability. He
was first seen at our clinic at age of 2 years. He was clin-
ically normal, apart from an abnormal head tilt second-
ary to abnormal neck posturing. His height was -3SD
and he had a stretched penile length of 0.5 cm (−5.3 SD)
with non-palpable testes. The patient had craniosynosto-
sis causing plagiocephaly. Hypopituitarism was con-
firmed (Table 1). An MRI of his pituitary gland showed
a small rudimentary adenohypophysis and a normal
pituitary stalk present with normally placed neurohyp-
ophysis. A skeletal survey showed closure of sagittal
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suture causing dolichocephaly and thoracic scoliosis.
L-thyroxine (50 mcg daily), hydrocortisone (2.5 mg twice
daily) and GH injections (0.035 mg/kg/day) were initiated.
Orchipexy was performed at the age of 2.5 years. Testos-
terone therapy (25 mg monthly) was given for 3 months
which improved penile length to 1.5 cm. Two other tes-
tosterone courses were given at the age of 5 years and
10 years with a partial improvement in penile length to
3 cm. Bilateral moderate SNHL was also found at the age
of 3 years. His growth improved in response to GH
Fig. 1 Family pedigrees, genotypes, growth charts for patients and clinical presentation. a, b Pedigrees of the families studied with CPHD3 demonstrating
the recessive inheritance pattern. Filled symbols indicate affected individuals. The respective genotype is indicated below each individual. Symbols are: + for
wild type allele;—for mutated allele. c, d, e Representative growth chart for Patients II:2 (Family 1), II:2 (Family 2) and II:4 (Family 2) showing reduced growth
velocity for all patients and reduced response for patient 2 and 3 compared to patient 1. Affected patient 2 (II:2 from family 2) showing f neck rotation, g
scoliosis and h lower thoracic scoliosis by spine x-ray. i, j Multisequential multiplanar brain MRI reveals pituitary gland hypoplasia for patient II:2 from family
1 i coronal view j sagittal view k skull x-ray demonstrates an increased anterior-posterior diameter of calvarium suggestive of dolicocephaly
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treatment; he had a growth velocity of 3–4 cm per year.
His height was 110 cm at the age of 10 years (−4SD). The
prescribed dose for GH injections was 0.035 mg/kg/day;
however the patient was not compliant with treatment,
which negatively affected the growth velocity and the
ultimate height at the age of 10 years.
Patient 3, Family 2
The younger sister (II:4, Fig. 1b) of the patient 2 was
born via normal vaginal delivery at 39 weeks of
gestation. Her birth weight (2.9 kg) and birth length
(46 cm) was adequate for gestational age. She also pre-
sented with jitteriness secondary to hypoglycemia at 2nd
month of age and was suspected to have hypopituitarism
(Table 1), because her older brother had been diagnosed
with the same condition before. Treatment thyroxine,
hydrocortisone and GH injections were started. She has
moderate SNHL and a normal skeletal survey. Magnetic
resonance imaging showed a normal pituitary gland.
Clinical features and hormonal levels for all three
affected patients are summarized in Table 1.
Genetic analyses
Genomic DNA extraction was carried out using PURE-
GENE DNA Extraction Kit according to manufacturer’s
instructions (Gentra Systems, Minneapolis, MN) from
Table 1 Clinical data for three patients with novel LHX3 mutations
Patient 1 (II:2, Family 1) Patient 2 (II:2, Family 2) Patient 3 (II:4, Family 2)
Age, years 7 11 2
Gestational age, weeks 39 39 39
Birth weight, kg (SD) 3.2 (0SD) 3 (− 0.7SD) 2.9 (− 0.7SD)
Birth length, cm (SD) 45 (−2.5SD) NA 46 (−1.8SD)
Age of onset, months 3 2 2
Initial manifestation hypopituitarism + + +
Basal GH μg/L (>10) <0.2 <0.5 <0.5
TSH mU/L (0.27–4.2) 0.02 0.04 0.4
PRL μg/L (2.5–15) 0.1 0.1 NA
LH U/L (0.1–3.3) <0.1 <0.1 <0.1
FSH U/L (0.1–7) <0.1 <0.1 <0.1
ACTH ng/L (5–60) 6 8 16
cortisol nmol/L (190–750) 70 62 102
FT4 pmol/L (12–22) 4.4 9.3 10.3
IGF1 ng/L (115–498) <25 <25 NA
IGFBP3 mg/L (0.7–3.6) <0.5 <0.3 NA
Hypolplastic pituitary gland + + -
Limited neck rotation + + -
SNHL + + +
Developmental delay (Mild) + + +
Other findings Dolichocephaly, Hypolasia of facial bones,




Mutation Identified c.437G > T (p. Cys146Phe) Homozygous c.466C > T (p. Arg156Ter) Homozygous
Type of mutation Missense mutation Nonsense
Effect on protein Location a well-established domain Null mutation
Computation (in silico) predictive
analysis
“Damaging” “Damaging”
Population data Not annotated as polymorphism Not annotated as polymorphism
Functional data Located in functional domain Located in functional domain
Allelic and family segregation data Recessive mutation and strong
segregation
Recessive mutation and strong
segregation
Other Evidence Relevant to patient’s phenotype Relevant to patient’s phenotype
Variant classification (ACMG) Likely pathogenic Pathogenic
NA not available
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the venous blood samples collected from each subject.
All exons and adjacent exon-intron boundaries of the
both LHX3 transcripts were amplified in Veriti® 96-Well
Fast Thermal Cycler (Applied Biosystems, Foster City,
CA) using HotStar Taq DNA Polymerase (Qiagen,
Germantown, MD). Primers were designed by the use of
Primer3 web based server (http://frodo.wi.mit.edu/pri-
mer3/; sequences of primers used for PCR amplification
are listed in Table 2). The PCR products were sequenced
by dye termination sequencing using BigDye® Termin-
ator Cycle Sequencing v3.1 Kit and ABI Prism 3730
Genetic Analyzer (Applied Biosystems, Inc., Foster City,
CA, USA). Sequence analysis was performed using the
SeqMan 6.1 module of the Lasergene (DNA Star Inc.
WI, USA) software package and the results were
compared with reference sequence. Accession numbers:
Nucleotide and amino acid numbering are for
LHX3, variant 2 (also known as isoform b) and cor-
respond to NCBI reference sequence accession number
NM_014564.3 for the cDNA and NP_055379.1 for the
protein.
In silico prediction and pathogenicity assessment
For interpretation of the identified sequence variants as
per ACMG guidelines, PolyPhen2 (Polymorphism phe-
notyping; http://genetics.bwh.harvard.edu/pph2/), SIFT
(Sorting Intolerant From Tolerant; http://sift.jcvi.org/)
and MutationTaster (http://www.mutationtaster.org/)
were used for pathogenicity assessment [10]. Project
HOPE ([11]; http://www.cmbi.ru.nl/hope/) was used to
predict the possible structural changes in the mutant
protein using a normal LHX3 structure (PDB-file:
2JTN). The sequences form the Homo Sapiens LHX3
protein and homologous proteins from other eukaryotic
species were obtained from the National Center for Bio-
technology Information (NCBI; http://www.ncbi.nlm.-
nih.gov/). A multiple alignment between these proteins
was performed using Clustal Omega (http://www.ebi.a-
c.uk/Tools/msa/clustalo/).
Results
Sanger sequencing of LHX3 gene in the affected boy
(II:2 from pedigree, Fig. 1a) from the first consanguin-
eous family led us to the identification of a homozygous
nucleotide change (c.437G > T), resulting in a cysteine-
to-phenylalanine substitution at 146 amino acid of the
encoded protein (p. Cys146Phe) (Fig. 2a). In the two sibs
(II:2 & II:4 from pedigree, Fig. 1b) from the second
family, we identified homozygosity for a single base ex-
change (c.466C > T). At the protein level, this transition
predicts change of amino acid 156 from arginine to a
stop codon (p. Arg156Ter) (Fig. 2b). Parents and siblings
of the affected patients were all healthy and show no
signs or symptoms related to the disorder. In addition,
they were either heterozygous or wild type for the iden-
tified mutations (Fig. 1a and b). p. Cys146Phe is pre-
dicted to be “damaging” based on PolyPhen2, SIFT and
MutationTaster. p. Arg156Ter is also predicted to be
“disease causing” by MutationTaster. Both the alterations
were not annotated in either dbSNP [12], the 1000 Ge-
nomes Project database [13], or Exome Aggregation
Consortium (ExAC) [14] and were absent in 400 normal
chromosomes of ethnically matched controls, preclud-
ing that these represented benign or more common
polymorphisms.
The identified p. Cys146Phe substitution resides in the
LIM2 domain of the LHX3 protein (Q9UBR4). LIM
domain is recognized as a tandem zinc-finger (Znf)
structure that functions as a modular protein-binding
interface and LIM homeodomain proteins have been
shown to play roles in cytoskeletal organization, organ
development, cell adhesion, cell motility and signal
transduction [15, 16]. Znf motif mostly contain a pattern
of cysteine and histidine residues that coordinately bind
to zinc ions at the base of each of the two ‘fingers’, but in
some cases they bind other metals such as iron, or no
metal at all [17]. The cysteine at position 146 is a zinc
ligating residue, involved in binding with the zinc cation
(Fig. 2c). A three-dimensional-structure prediction
analysis for p. Cys146Phe mutation by project HOPE
predicts that the mutant residue (phenylalanine) will
probably not fit in place of the smaller size wild-type
cysteine residue which is buried in the core of the pro-
tein and will thus disturb the possible rearrangements of
surrounding residues. In addition, the replacement of
cysteine at p.146 will disrupt the putative interaction
with zinc cation, thus affecting biological activity of
LHX3. This cysteine is entirely conserved in LHX3
Table 2 Sequences of oligonucleotide primers used for PCR amplification
Primer Sense Strand Antisense Strand
LHX3_Exon 1a 5′- CAACCCAGCCAGGGAG - 3′ 5′- GTTTCCATCTCTGTGTCCCG - 3′
LHX3_ Exon 1b 5′- CCCGGAGTCGCTTGGAC - 3′ 5′- GCCCAGATCCTCTAGCTCC - 3′
LHX3_ Exon 2 5′- CAGCCCTGAGTCCTGTGG - 3′ 5′- TGATTGTGAGGGGAGGAGTC - 3′
LHX3_ Exon 3 5′- CGGACAGAGCCTTCCTC - 3′ 5′- GGAGAGAATTTCCCCGGAC - 3′
LHX3_ Exon 4 + 5 5′- CTTCCGAGAAGCCTGTG - 3′ 5′- TCCATGGGAAATTCAGATCC - 3′
LHX3_ Exon 6 5′- CTGCAGGATGGGACTCTG - 3′ 5′- CACCAGCCCTCCCTTGAC - 3′
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Fig. 2 Identification of two novel mutations in LHX3. a Sequencing chromatogram indicating the homozygous wild type, heterozygous carrier
and homozygous mutant forms. Homozygous c.437 G > T (p. Cys146Phe) mutation is identified in affected individual (II:2, family 1). b Homozygous c.466
C > T (p. Arg156Ter) mutation is identified in affected individuals (II:2 & II:4, family 2). Nucleotide and amino acid numbering correspond to NM_014564.3
for the cDNA and NP_055379.1 for the protein. Nucleotides were numbered using A of the ATG translation initiation codon as +1 nucleotide of the
coding sequence. Mutations are highlighted (arrow). c Ribbon/Cartoon-presentation of zinc finger motif of the LHX3 consisting of α-helix (green) and
β-sheets (brown). The Zn binding residues of LIM domains are highly conserved; cysteine at position 146 (yellow) is a zinc ligating residue, involved in
binding with the zinc cation (brown). d The multiple-sequence alignment was generated with the Clustal Omega Multiple Sequence Alignment tool
and depicts conservation of the crucial p. Cys146 residue during evolution. Asterisk (*) indicates positions which have a single, fully conserved residue.
Colon (:) indicates conservation between groups of strongly similar properties - scoring > 0.5. e LHX3 mutations associated with combined pituitary
hormone deficiency. Schematic representation of intron-exon structure of LHX3 gene, domain graph of the encoded protein (Uniprot identifier:
Q9UBR4), and the genetic variants. Exons are designated as boxes 1–6 and introns are shown by thin lines. A full-length wild type LHX3 protein is
shown, with its N-terminus and C-terminus. Alternative splicing generates two isoforms, LHX3a and LHX3b, which are 397 and 402 amino acids long
respectively. The isoforms differ only in the amino-terminal domains. Other known functional domains are following: LIM domains (LIM); homeodomain
(HD), and carboxyl trans-activation domain (LSD). Novel variants identified in our study are boxed in red alongside previously reported variants in HGMD
database [28]. The mutations are grouped according to canonical classes and further identified by their amino acid changes
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proteins in homologous sequences (Fig. 2d). It is part of
the amino acid sequence ‘signature’ that defines the LIM
domains proteins [18], indicating that the Cys146 resi-
due is critical to overall LHX3 function. The identified
nonsense mutation p. Arg156Ter is predicted to result
in a premature stop codon, loss of entire DNA-binding
homeodomain and carboxyl terminus causing the pro-
duction of short, inactive LHX3 protein or non-sense
mediated decay of the aberrant mRNA. Mutant LHX3
proteins lacking a homeodomain do not bind DNA and
thus do not induce transcription from pituitary genes. A
complete loss of function is assumed with this homozy-
gous mutation.
Hence, the factors that p. Arg156Ter being a null vari-
ant and critical location of p. Cys146Phe in a well-
established domain, their absence in population data/con-
trols, computational evidence, segregation analysis and
relevance to the patients phenotype, led us to classify
these allelic variants; p. Arg156Ter and p. Cys146Phe as
“pathogenic” and “likely pathogenic” respectively, accord-
ing to the recommendations of ACMG guidelines [10] for
the interpretation of sequence variants (see Table 1).
Discussion and conclusions
Pituitary organogenesis is a highly complex process and
tightly regulated cascade of several transcription activa-
tors and repressors, and signaling molecules [19, 20].
Anterior pituitary ontogenesis begins early around em-
bryonic day (E) 7.5, corresponding to the first
visualization of the pituitary placode. Briefly, during the
early stage of pituitary development, which corresponds
to E6.5-10.5 in mice, the extrinsic signaling pathways are
activated, including bone morphogenetic protein (BMP2,
BMP4), fibroblast growth factor (FGF8, 10 and 18),
Sonic Hedgehog (SHH) and wingless (WNT4) pathways
[21]. Within the developing Rathke’s pouch and anterior
pituitary, a number of transcription factors are involved
in a timely manner during the steps of differentiation;
early acting such as paired homeodomain transcription
factors (HESX1, PITX1, PITX2), LIM homeobox (LHX3,
LHX4) or late-acting such as PROP1 (prophet of Pit-1)
and POU1F1 (previously called PIT-1) [22]. Lhx3 gene
expression is detected in the developing nervous system
and Rathke’s pouch at approximately E9 [6]. By E12,
POU1F1 synergistically partners with PITX1 and PITX2
for the differentiation of specific pituitary-specific cell
types; thyrotropes, lactotropes and somatotropes [23].
The gonadotrope and thyrotropic precursors are acti-
vated by zinc-finger transcription factor, GATA2 in
response to inductive interaction of LHX3 and BMP2
signaling [20]. Terminal differentiation of the pituitary
completes at approximately E17 in response to the
tightly controlled temporospatial gradient expression of
transcription factor [7, 24]. A simplified scheme of
expression of the transcription factors is given in Fig. 3.
In Lhx3 null mutant mice, Rathke’s pouch is initially
formed but then fails to grow resulting in either stillbirth
or death shortly following birth, thus providing a genetic
paradigm for the study of pituitary development [25].
LHX3 is known to plays an essential role in the proper
development of the spinal motoneurons (which likely
explains neck rotation anomalies in human with LHX3
mutation) and is also expressed in the auditory system
[4, 26, 27]. Only a small number of studies have previ-
ously reported the clinical phenotype and genetic basis
of LHX3 patients (Human Gene Mutation Database
Fig. 3 A simplified scheme of the development cascade representing the main transcription factors expression during pituitary development (adapted
from de Moraes et al. [20]). Pituitary cell lineages are determined by the activation or repression of each transcription factor. LHX3 participates in the
pituitary cell differentiation and maturation process. The anterior pituitary consists of five distinct cell types. These cells and their specific hormones are
lactotropes, which produce PRL; somatotropes, which produce GH; gonadotropes, which produce LH and FSH; corticotropes, which produce ACTH;
and thyrotropes, which produce TSH. Any mutation that alters the length, quality or quantity of any gene involved in the development cascade will
result in pituitary development failure
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[28]). Together with two novel mutations identified in
our study, there are now 16 different LHX3 variants
(Fig. 2e) in patients with CPHD3 phenotype as detailed
in Table 3. The clinical phenotypes of human LHX3
mutations encompass a varied presentation. The earliest
descriptions of LHX3 mutations were associated with
panhypopituitarism without ACTH deficiency or any
extrapituitary phenotypes [29]. Later, a rigid cervical
spine with limited head rotation, mental retardation and
MRI findings of a hypodense lesion in the pituitary was
also reported in addition to CPHD [30]. Four homozy-
gous LHX3 mutations with CPHD, with or without
limited neck rotation were identified in a cohort of 366
patients with hypopituitarism or CPHD. Hearing status
in these patients was not documented to be either nor-
mal or with any hearing deficit [31]. Bilateral SNHL was
first associated as an additional CPHD3 phenotype in
the four patients with CPHD, severe pituitary hypoplasia,
ACTH deficiency and skeletal abnormalities [32]. The
occurrence of SNHL was explained by expression of
LHX3 in a pattern overlapping that of SOX2 in the sen-
sory epithelium of developing inner ear [32]. Later, six
patients from a same genealogy with CPHD, restricted
neck rotation, scoliosis and congenital hearing impair-
ment were described to harbor a recessive novel splice
acceptor site mutation [33]. More recently, a complete
loss of function mutation is associated with CPHD
including ACTH deficiency, short neck and SNHL [5].
Compound heterozygous LHX3 defects in a nonconsan-
guineous patient with syndromic CPHD, severe scoliosis
and normal intelligence and a novel homozygous muta-
tion p.T194R were recently reported [34, 35].
A candidate-gene approach was used on the basis of
documented pituitary abnormalities, restricted neck
rotation and SNHL, LHX3 gene was then sequenced.
Herein, we characterize two novel mutations in three
patients from two unrelated Saudi consanguineous
families. The three patients presented with early infantile
hypoglycemia and deficiency of all anterior pituitary hor-
mones including ACTH. Two of the affected patients
also displayed rigidity of the cervical spine and short
neck with limited rotation. Clinically, there was no
evidence of cardiac defects or skin manifestations as
reported earlier in some reports [32, 34]. Birth length in
one of our patients was slightly below the mean centile
for gestational age, which supports earlier findings that
IGFs are necessary for that period but the severe defi-
ciency interacts with intrauterine longitudinal growth
[33]. Hearing impairment was noticed for all three
affected at the age of 2–3 years, audiologic assessment
later confirmed moderate SNHL that was partially man-
aged with hearing aids and all had receptive and expres-
sive language delay. Perinatal mortality has been
reported in other families with LHX3 mutations; our
study family 1 had a baby girl who died at an early age
probably due to the similar phenotype. Both the male
Table 3 LHX3 mutations in patients with CPHD3 phenotype
No. Mutation Amino acid change Mutation Type Reference
Authors Journal [Reference No]
1 c.148A > T Lys50Ter Nonsense Rajab A et al. Hum Mol Genet 2008 [32]
2 c.229C > T Arg77Ter Nonsense Bonfig W et al. Eur J Pediatr 2011 [5]
3 c.347A > G Tyr116Cys Missense Netchine I et al. Nat Genet 2000 [29]
4 c.368G > A Cys123Tyr Missense Sobrier M et al. J Clin Endocrinol Metab 2012 [35]
5 c.437G > T Cys146Phe Missense Ramzan K et al. BMC Endocr Disord
6 c.466C > T Arg156Ter Nonsense Ramzan K et al. BMC Endocr Disord
7 c.581A > G Gln194Arg Missense Bechtold-Dalla Pozza S et al. Horm Res Paediatr 2012 [34]
8 c.644C > T Ala215Val Missense Pfaeffle R et al. J Clin Endocrinol Metab 2007 [31]
9 c.687G > A Trp229Ter Nonsense Pfaeffle R et al. J Clin Endocrinol Metab 2007 [31]
10 c.267-3C > G Splicing Sobrier M et al. J Clin Endocrinol Metab 2012 [35]
11 c.470-2 A > G Splicing Kristrom B et al. J Clin Endocrinol Metab 2009 [33]
12 c.111delT Gly38Alafs*140 Deletion Bhangoo A et al. J Clin Endocrinol Metab 2006 [30]
13 c.302_303delG CinsTCCT Gly101Valfs*78 Small indel Pfaeffle R et al. J Clin Endocrinol Metab 2007 [31]
14 <1.4 Mb incl. entire gene Gross deletion Pfaeffle R et al. J Clin Endocrinol Metab 2007 [31]
15 23 bp E3I3-3 to E3I3 + 20 Gross deletion Netchine I et al. Nat Genet 2000 [29]
16 3088 bp incl. ex. 2-5 Gross deletion Rajab A et al. Hum Mol Genet 2008 [32]
Nucleotide and amino acid numbering are based on LHX3, variant 2 (also known as isoform b) and correspond to NCBI reference sequence accession number
NM_014564.3 for the cDNA and NP_055379.1 for the protein. Nucleotide numbering commenced with the A of the ATG translation initiation codon as +1
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patients had markedly delayed pubertal development
and micropenis symptom, which can thus facilitate the
diagnosis in case of a male child. Short neck and neo-
natal hypoglycemia may be overlooked in neonatal cases,
but the prolonged jaundice and hypothyroidism should
lead to the diagnosis of CPHD.
The incidence of reported mutations in LHX3 gene
remains low. Clinical, hormonal and radiological work-
up is very important to better determine which
transcription factor should be screened. We suggest that
the presence of SNHL and limited neck rotation be
considered in the differential diagnosis of CPHD3 to
facilitate molecular diagnosis. The identification of a
LHX3 mutation at an early age is likely to be beneficial
for patients to start an appropriate replacement of
hormone deficiencies, auditory testing to allow regular
speech development, counseling for limitations of
cervical mobility and development of scoliosis, and for
continual monitoring of these patients. The importance
to characterize the patients with CPHD should be
emphasized to physicians and researchers to help the
genetic screening of patients, and to assist genetic coun-
seling and prenatal diagnosis.
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